Trends in the use of postoperative radiotherapy for resected non-small-cell lung cancer

被引:40
作者
Bekelman, Justin E.
Rosenzweig, Kenneth E.
Bach, Peter B.
Schrag, Deborah
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Hlth Outcomes Res Grp, New York, NY 10021 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2006年 / 66卷 / 02期
关键词
non-small-cell lung cancer; postoperative radiotherapy; health services research; practice patterns; SEER;
D O I
10.1016/j.ijrobp.2006.04.032
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Purpose: A 1998 meta-analysis of postoperative radiotherapy (PORT) for non-small-cell lung cancer (NSCLC) found that PORT did not improve outcomes. Yet practice guidelines differ in their recommendations with regard to PORT use. We examine temporal trends in PORT use before and after the 1998 meta-analysis. Methods and Materials: Using data from the Surveillance, Epidemiology, and End Results (SEER) Program, we identified 22,953 patients with Stage I, II, or IIIA NSCLC who had resection between 1992 and 2002 in the United States and characterized each patient according to nodal status (N0, N1, or N2 disease). We measured use of PORT by calendar year. We examined the association between clinical and demographic characteristics and receipt of PORT using logistic regression. Results: For N0, N1, and N2 NSCLC, PORT use has declined. The proportion of patients with NO disease receiving PORT declined from 8% in 1992 to 4% in 2002. For patients with N1 disease, PORT use declined from 51 % in 1992 to 19 % in 2002; and for patients with N2 disease, PORT use declined from 65 % in 1992 to 37 % in 2002. Conclusion: In the context of uncertainty about what constitutes optimal adjuvant treatment for resected NSCLC, PORT use has substantially declined. (c) 2006 Elsevier Inc.
引用
收藏
页码:492 / 499
页数:8
相关论文
共 23 条
[1]
[Anonymous], 2002, AJCC CANC STAG MAN
[2]
Using practice guidelines to assess cancer care quality [J].
Bach, PB .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) :9041-9043
[3]
Adjuvant chemotherapy for lung cancer - A new standard of care [J].
Blum, RH .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (04) :404-405
[4]
Balancing the possible effectiveness of postoperative radiotherapy for non-small-cell lung cancer against the possible detriment of radiation-induced toxicity [J].
Bonner, JA ;
Tincher, SA ;
Fiveash, JB .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (19) :3905-3907
[5]
Burdett S, 1998, LANCET, V352, P257
[6]
Ettinger D S, 2001, Cancer Control, V8, P22
[7]
Fritz A., 2000, International classification of diseases for oncology
[8]
Treatment and survival after lung resection for non-small cell lung cancer in patients with microscopic residual disease at the bronchial stump [J].
Ghiribelli, C ;
Voltolini, L ;
Paladini, P ;
Luzzi, L ;
Di Bisceglie, M ;
Gotti, G .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 1999, 16 (05) :555-559
[9]
Microscopic (R1) and macroscopic (R2) residual disease in patients with resected non-small cell lung cancer [J].
Hofmann, HS ;
Taege, C ;
Lautenschläger, C ;
Neef, H ;
Silber, RE .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2002, 21 (04) :606-610
[10]
Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer [J].
Le Chevalier, T ;
Arriagada, R ;
Le Péchoux, C ;
Grunenwald, D ;
Dunant, A ;
Pignon, JP ;
Tarayre, M ;
Abratt, R ;
Arriagada, R ;
Bergman, B ;
Gralla, R ;
Grunenwald, D ;
Le Chevalier, T ;
Orlowski, T ;
Papadakis, E ;
Pinel, MIS ;
Araujo, C ;
Della Torre, H ;
de Solchaga, MM ;
Abdi, E ;
Blum, R ;
Ball, D ;
Basser, R ;
De Boer, R ;
Bishop, J ;
Brigham, B ;
Davis, S ;
Fox, D ;
Richardson, G ;
Wyld, D ;
Pirker, R ;
Humblet, Y ;
Delaunois, L ;
Van Meerbeeck, JP ;
Germonpre, P ;
Vansteenkiste, J ;
Nackaerts, K ;
Pinel, MIS ;
Vauthier, G ;
Younes, RN ;
Arriagada, R ;
Baeza, R ;
Carvajal, P ;
Kleinman, S ;
Orlandi, L ;
Castro, C ;
Godoy, J ;
Kosatova, K ;
Gaafar, R ;
Azarian, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (04) :351-360